By Stephen Levin
During the peak of the drug-eluting stent (DES) wave in the early to mid 2000s, cardiovascular conferences actually entertained discussions as to whether the era of significant innovation in interventional technology for treating vascular disease had been brought to an end by DES, leaving only small niche opportunities remaining
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?